Paper Details

  1. Home
  2. Paper Details

Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.

Author: AgarwalKosh, BentleyRoy, DusheikoGeoffrey, MarcellaStephen, OrmeMichelle E, Peck-RadosavljevicMarkus, PerardRodolphe, WedemeyerHeiner, YoshijiHitoshi

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

Lusutrombopag, an oral thrombopoietin receptor agonist, has been shown to reduce the need for preoperative platelet transfusions in patients with chronic liver disease and severe thrombocytopenia. This analysis assessed the efficacy and safety of lusutrombopag in these patients undergoing planned invasive procedures.
Paper Details　
Original Abstract of the Article :
Lusutrombopag is an oral thrombopoietin receptor agonist (TPO-RA). Clinical trials have shown lusutrombopag's efficacy in reducing need for preoperative platelet transfusion in patients with chronic liver disease (CLD) and severe thrombocytopenia. This analysis assessed efficacy and safety of lusutr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402754/

データ提供：米国国立医学図書館（NLM）

Lusutrombopag: A New Hope for Severe Thrombocytopenia

This study investigates the effectiveness and safety of lusutrombopag, a drug used to treat severe thrombocytopenia, a condition characterized by low platelet counts, in patients with chronic liver disease. It's like finding a new oasis in the desert of liver disease, offering a vital source of support for patients struggling with this condition. The researchers found that lusutrombopag effectively increased platelet counts, reducing the need for transfusions and improving outcomes for these patients.

Lusutrombopag: A Lifeblood for Liver Disease Patients

This study explores the efficacy and safety of lusutrombopag, a drug used to treat severe thrombocytopenia in patients with chronic liver disease. The researchers found that lusutrombopag effectively increased platelet counts, offering a promising treatment option for these patients, who often face the challenge of low platelet counts.

A New Oasis in the Desert of Liver Disease

This study highlights the potential of lusutrombopag in treating severe thrombocytopenia in patients with chronic liver disease, offering a new ray of hope for these individuals. It's like finding a new wellspring of water in a parched desert, providing a much-needed solution to a challenging health problem.

Dr. Camel's Conclusion

This research underscores the importance of developing effective treatments for patients with chronic liver disease, a condition that affects millions worldwide. It's like being a vigilant desert nomad, always on the lookout for resources and solutions to overcome the challenges of a harsh environment.
Date :
  1. Date Completed 2022-08-26
  2. Date Revised 2022-09-23
Further Info :

Pubmed ID

35836089

DOI: Digital Object Identifier

PMC9402754

Related Literature

Article Analysis
・Effects of lusutrombopag
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.